A Phase II Study of Erlotinib in Combination With Capecitabine as First-Line Treatment in Elderly Patients With Stage IIIB/IV Adenocarcinoma Non-Small Cell Lung Cancer (NSCLC).

Trial Profile

A Phase II Study of Erlotinib in Combination With Capecitabine as First-Line Treatment in Elderly Patients With Stage IIIB/IV Adenocarcinoma Non-Small Cell Lung Cancer (NSCLC).

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Capecitabine (Primary) ; Erlotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Feb 2012 Actual patient number (62) added as reported by ClinicalTrials.gov.
    • 28 Feb 2012 Actual end date (March 2011) added as reported by ClinicalTrials.gov.
    • 28 Feb 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top